Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 1

Interventions

Ipilimumab 17 Nivolumab 15 incomplete Freund's adjuvant 8 Cyclophosphamide 7 CTLA-4 Antigen 7 pembrolizumab 6 Ranibizumab 6 sargramostim 5 Radiosurgery 5 Blood Specimen Collection 5 tebentafusp 4 Temozolomide 4 Surveys and Questionnaires 4 Magnetic Resonance Spectroscopy 4 MART-1 Antigen 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Biopsy 4 Bevacizumab 4 fludarabine phosphate 3 fludarabine 3 aflibercept 3 Thalidomide 3 Sunitinib 3 Specimen Handling 3 MAGEA3 protein, human 3 Interleukin-2 3 130-nm albumin-bound paclitaxel 3 relatlimab 2 olaparib 2 montanide ISA 51 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Uveal Melanoma × quisinostat × Clear all

NCT06932757 2025-06-03

Adjuvant Quisinostat in High-Risk Uveal Melanoma

University of Miami

Phase 2 Recruiting

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡